Lacosamida Aurovitas (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons. This stabilizes hyper‑excitable neuronal membranes, reduces repetitive firing, and helps prevent the abnormal electrical activity that leads to seizures.

The dosing regimen for lacosamide is individualized. A qualified prescriber determines the appropriate dose and titration schedule based on the patient’s clinical condition, response, and any relevant laboratory values.

Safety data for lacosamide in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks and discuss alternative options when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many older agents that target fast inactivation. Compared with drugs such as carbamazepine, lacosamide often has a lower risk of drug‑induced hyponatremia and may be better tolerated in patients who experience cognitive side effects from other medications.

Lacosamida Aurovitas should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from excess moisture and direct sunlight to maintain its stability.

The medication is taken orally, usually as tablets or capsules, with or without food. Patients should follow the administration instructions provided by their healthcare professional.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, hypersensitivity reactions including anaphylaxis, and mood changes that may lead to suicidal thoughts. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to lacosamide or any component of the formulation should avoid the product. Caution is also advised for individuals with significant cardiac conduction disorders, severe renal impairment, or uncontrolled hepatic disease, and the medication should be used only under medical supervision in these cases.